One tablet contains 0.02 mg clenbuterol hydrochloride.
For prolonged treatment of bronchospastic syndrome in mild and moderate atopic and non-atopic bronchial asthma; strain-induced bronchospasm; in the complex therapy of chronic spastic bronchitis and COPD.
Adults: 0,02 mg orally, morning and evening; Maintenance dose – 0,01 mg 2 times daily. In more serious conditions, 0,04 mg, 2 times daily (morning and evening) should be administered in the first days. The dose should be reduced upon condition improving. In children: 6-12 years –1/2 tablet 2 times daily. Over 12 years –1/2 tablet 2-3 times daily or 1 tablet 2 times daily.
Hypersensitivity to the product; thyrotoxicosis; digitalis intoxication, tachycardia, tachyarrhythmia, hyperthrophic obstructive cardiomyopathy; first trimester of pregnancy.
Beta-blockers antagonize Clenbuterol effects. In concomitant administration with antidiabetics, their dose should be increased due to glycogenolysis stimulation by Clenbuterol. Co-administration with cardiac glycosides, MAO-inhibitors and theophylline may cause heart rhythm disorders.
The effect of Clenbuterol is potentiated by tricyclic antidepressants, some antihistamines and levothyroxin and reduced by some antihypertensive products (guanethidine). Halothane and other halogenated hydrocarbon anesthetics and cyclopropane sensitize myocardium and may potentiate the arrhythmogenic effect of в2- sympathomimetics.